Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Human rotavirus liquid vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Human rotavirus liquid vaccine | BIOLOGICAL | - |
Inclusion Criteria: * Healthy male or female infant between, and including, 6 and 10 weeks of age with a birth weight of \> 2000 grams. * Written informed consent obtained from the parent or guardian of the subject. Exclusion Criteria: * Use of any investigational or non-registered product (drug ...
Human rotavirus liquid vaccine is an investigational vaccine being studied for the prevention of rotavirus infections, which cause severe diarrhea in infants and young children. It is currently in Phase 3 clinical development and has not been approved by regulatory authorities.
Human rotavirus liquid vaccine is being developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The vaccine is currently in Phase 3 clinical trials for rotavirus infection prevention.
Human rotavirus liquid vaccine is in Phase 3 clinical development. It is an investigational vaccine and has not yet received regulatory approval. A Phase 3 trial has been completed, evaluating the vaccine's immunogenicity, reactogenicity, and safety in infants.
Human rotavirus liquid vaccine has one completed Phase 3 clinical trial, NCT00345956, which evaluated the immunogenicity, reactogenicity, and safety of two doses of the vaccine in infants in Vietnam. The trial enrolled 375 participants, all healthy infants aged 6 weeks and older.
Human rotavirus liquid vaccine is classified as a monoclonal antibody modality, though it is being developed as a vaccine to prevent rotavirus infection. It is currently in Phase 3 clinical trials and remains investigational, with no approval status confirmed.